DK1948789T3 - Fremgangsmåde til fremstilling af permanente, humane cellelinjer - Google Patents

Fremgangsmåde til fremstilling af permanente, humane cellelinjer

Info

Publication number
DK1948789T3
DK1948789T3 DK06818078.5T DK06818078T DK1948789T3 DK 1948789 T3 DK1948789 T3 DK 1948789T3 DK 06818078 T DK06818078 T DK 06818078T DK 1948789 T3 DK1948789 T3 DK 1948789T3
Authority
DK
Denmark
Prior art keywords
human cell
preparation
cell lines
permanent human
expression
Prior art date
Application number
DK06818078.5T
Other languages
English (en)
Inventor
Gudrun Schiedner
Christoph Volpers
Original Assignee
Cevec Pharmaceuticals Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cevec Pharmaceuticals Gmbh filed Critical Cevec Pharmaceuticals Gmbh
Application granted granted Critical
Publication of DK1948789T3 publication Critical patent/DK1948789T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0605—Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0623—Stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/04—Immortalised cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/06—Uses of viruses as vector in vitro

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Molecular Biology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK06818078.5T 2005-11-16 2006-11-15 Fremgangsmåde til fremstilling af permanente, humane cellelinjer DK1948789T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102005054628A DE102005054628A1 (de) 2005-11-16 2005-11-16 Verfahren zur Herstellung von permanenten humanen Zelllinien
PCT/DE2006/002004 WO2007056994A2 (de) 2005-11-16 2006-11-15 Verfahren zur herstellung von permanenten humanen zelllinien

Publications (1)

Publication Number Publication Date
DK1948789T3 true DK1948789T3 (da) 2010-10-11

Family

ID=37770340

Family Applications (1)

Application Number Title Priority Date Filing Date
DK06818078.5T DK1948789T3 (da) 2005-11-16 2006-11-15 Fremgangsmåde til fremstilling af permanente, humane cellelinjer

Country Status (19)

Country Link
US (2) US8936908B2 (da)
EP (1) EP1948789B1 (da)
JP (1) JP5213719B2 (da)
KR (1) KR101244529B1 (da)
CN (1) CN101310014B (da)
AT (1) ATE470702T1 (da)
AU (1) AU2006314931B2 (da)
CA (1) CA2629211C (da)
CY (1) CY1110734T1 (da)
DE (2) DE102005054628A1 (da)
DK (1) DK1948789T3 (da)
ES (1) ES2345508T3 (da)
IL (1) IL190705A (da)
MY (1) MY144034A (da)
PL (1) PL1948789T3 (da)
PT (1) PT1948789E (da)
SG (1) SG173947A1 (da)
SI (1) SI1948789T1 (da)
WO (1) WO2007056994A2 (da)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005054628A1 (de) 2005-11-16 2007-05-24 Cevec Pharmaceuticals Gmbh Verfahren zur Herstellung von permanenten humanen Zelllinien
DE102009003439A1 (de) * 2009-02-05 2010-08-26 Cevec Pharmaceuticals Gmbh Neue permanente humane Zelllinie
CN101942413B (zh) * 2009-07-07 2015-02-11 翁炳焕 出生缺陷细胞库及其构建方法
JP5928843B2 (ja) 2010-08-16 2016-06-01 ツェヴェック ファーマシューティカルズ ゲゼルシャフト ミット ベシュレンクテル ハフツング インフルエンザウイルスを製造するための永久ヒト羊膜細胞株
EP2909228A1 (en) * 2012-10-19 2015-08-26 CEVEC Pharmaceuticals GmbH Production of a hcmv based vaccine in human amniocyte cell lines
EP2722337A1 (en) * 2012-10-19 2014-04-23 CEVEC Pharmaceuticals GmbH Production of a HCMV based vaccine in human amniocyte cell lines
WO2014115087A2 (en) 2013-01-22 2014-07-31 Cencor Biotech Ltd. A method for the preparation of recombinant human prothrombin and fibrinogen
CA2952121A1 (en) 2014-06-13 2015-12-17 Childrens' Medical Center Corporation Products and methods to isolate mitochondria
SG10202112057QA (en) 2015-05-12 2021-12-30 Sangamo Therapeutics Inc Nuclease-mediated regulation of gene expression
CN107849102B (zh) * 2015-05-15 2022-05-13 希望之城 嵌合抗原受体组合物
US20170151287A1 (en) 2015-11-30 2017-06-01 Flagship Ventures Management, Inc. Methods and compositions of chondrisomes
ES3057779T3 (en) 2016-01-15 2026-03-04 Childrens Medical Ct Corp Therapeutic use of mitochondria and combined mitochondrial agents
EP3736286A1 (en) 2019-05-09 2020-11-11 Biotest AG Single chain factor viii molecule
EP3785726A1 (en) 2019-09-02 2021-03-03 Biotest AG Factor viii protein with increased half-life
AU2020342349A1 (en) 2019-09-02 2022-03-03 Biotest Ag Factor VIII protein with increased half-life
WO2021165226A1 (en) 2020-02-17 2021-08-26 Biotest Ag Subcutaneous administration of factor viii
WO2022079083A1 (en) 2020-10-15 2022-04-21 F. Hoffmann-La Roche Ag Nucleic acid constructs for va rna transcription
US20220154223A1 (en) 2020-10-15 2022-05-19 Hoffmann-La Roche Inc. Nucleic acid constructs for simultaneous gene activation
CN118202060A (zh) 2021-10-05 2024-06-14 再生生物股份有限公司 用于重组aav生产的组合物和方法
WO2023060113A1 (en) 2021-10-05 2023-04-13 Regenxbio Inc. Compositions and methods for recombinant aav production
AR127674A1 (es) 2021-10-18 2024-02-21 Regeneron Pharma Células de mamífero que comprenden genes cas9 integrados para producir sitios de integración estables, y células de mamífero que comprenden sitios de integración estables y otros sitios
JP2024537896A (ja) 2021-10-18 2024-10-16 リジェネロン・ファーマシューティカルズ・インコーポレイテッド アデノウイルス随伴ウイルスポリヌクレオチドを含む真核細胞
EP4508241A1 (en) 2022-04-13 2025-02-19 F. Hoffmann-La Roche AG Method for determining aav genomes
EP4529614A1 (en) 2022-05-23 2025-04-02 F. Hoffmann-La Roche AG Raman-based method for the differentiation of aav particle serotype and aav particle loading status
JP2025519228A (ja) 2022-06-03 2025-06-24 エフ. ホフマン-ラ ロシュ アーゲー 組換えaav粒子を生成するための方法
WO2024013239A1 (en) 2022-07-14 2024-01-18 F. Hoffmann-La Roche Ag Method for producing recombinant aav particles
JP2025530294A (ja) 2022-09-12 2025-09-11 エフ. ホフマン-ラ ロシュ アーゲー 完全なaav粒子と空のaav粒子を分離するための方法
AU2024216670A1 (en) 2023-02-07 2025-07-31 F. Hoffmann-La Roche Ag Method for the detection of anti-aav particle antibodies
WO2024194280A1 (en) 2023-03-21 2024-09-26 F. Hoffmann-La Roche Ag Method for the production of recombinant aav particle preparations
AU2025218748A1 (en) 2024-02-09 2026-08-06 F. Hoffmann-La Roche Ag Method for producing recombinant adeno-associated viral particles
WO2025252480A1 (en) 2024-06-07 2025-12-11 F. Hoffmann-La Roche Ag Method for purifying plasmid dna
WO2026010927A2 (en) * 2024-07-01 2026-01-08 Forge Biologics, Inc. Producer cells for safer aav production
US20260022401A1 (en) 2024-07-22 2026-01-22 Hoffmann-La Roche Inc. Novel AAV rep ORFs and Rep polypeptides
WO2026037757A1 (en) 2024-08-13 2026-02-19 F. Hoffmann-La Roche Ag Modified aav particles
WO2026132012A1 (en) 2024-12-20 2026-06-25 F. Hoffmann-La Roche Ag Aav particle processing using affinity chromatography with gradient elution
WO2026132139A1 (en) 2024-12-20 2026-06-25 F. Hoffmann-La Roche Ag Purification process for viral vectors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6797495B2 (en) * 1996-11-05 2004-09-28 The Regents Of The University Of California Somatic cells with ablated PrP gene and methods of use
ES2378272T3 (es) 1999-04-15 2012-04-10 Crucell Holland B.V. Producción de proteína recombinante en una célula humana
US20050170463A1 (en) * 1999-04-15 2005-08-04 Abraham Bout Recombinant protein production in permanent amniocytic cells that comprise nucleic acid encoding adenovirus E1A and E1B proteins
US6855544B1 (en) * 1999-04-15 2005-02-15 Crucell Holland B.V. Recombinant protein production in a human cell
US6492169B1 (en) * 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
DE19955558C2 (de) 1999-11-18 2003-03-20 Stefan Kochanek Permanente Amniozyten-Zelllinie, ihre Herstellung und Verwendung zur Herstellung von Gentransfervektoren
US6558948B1 (en) * 1999-11-23 2003-05-06 Stefan Kochanek Permanent amniocytic cell line, its production and use for the production of gene transfer vectors
US6369448B1 (en) * 2000-01-21 2002-04-09 Lsi Logic Corporation Vertically integrated flip chip semiconductor package
NZ537277A (en) * 2002-07-18 2008-04-30 Crucell Holland Bv Recombinant production of mixtures of antibodies
NZ542585A (en) 2003-05-09 2007-11-30 Crucell Holland Bv Cultures of PER.C6-immortalized cells and processes for culturing the same to increase product yields therefrom
DE102005054628A1 (de) 2005-11-16 2007-05-24 Cevec Pharmaceuticals Gmbh Verfahren zur Herstellung von permanenten humanen Zelllinien

Also Published As

Publication number Publication date
US20150203813A1 (en) 2015-07-23
PT1948789E (pt) 2010-08-05
CA2629211A1 (en) 2007-05-24
IL190705A (en) 2012-04-30
WO2007056994A8 (de) 2007-07-19
AU2006314931A1 (en) 2007-05-24
US9315773B2 (en) 2016-04-19
US8936908B2 (en) 2015-01-20
SI1948789T1 (sl) 2010-08-31
KR20090114306A (ko) 2009-11-03
SG173947A1 (en) 2011-09-29
PL1948789T3 (pl) 2010-11-30
IL190705A0 (en) 2011-08-01
WO2007056994A2 (de) 2007-05-24
CN101310014B (zh) 2012-05-30
DE502006007198D1 (de) 2010-07-22
ES2345508T3 (es) 2010-09-24
CA2629211C (en) 2016-05-10
US20070111312A1 (en) 2007-05-17
MY144034A (en) 2011-07-29
DE102005054628A1 (de) 2007-05-24
JP2009515537A (ja) 2009-04-16
WO2007056994A3 (de) 2007-11-01
CN101310014A (zh) 2008-11-19
CY1110734T1 (el) 2015-06-10
KR101244529B1 (ko) 2013-03-18
EP1948789B1 (de) 2010-06-09
EP1948789A2 (de) 2008-07-30
AU2006314931B2 (en) 2011-08-18
ATE470702T1 (de) 2010-06-15
JP5213719B2 (ja) 2013-06-19

Similar Documents

Publication Publication Date Title
CY1110734T1 (el) Μεθοδος παραγωγης μονιμων ανθρωπινων κυτταρικων σειρων
EP2516624A4 (en) CELL LINE 3M
WO2009114702A3 (en) Recombinant production of authentic human proteins using human cell expression systems
MX347197B (es) Epitopes de celulas t reguladoras, composiciones y usos para los mismos.
WO2009149956A3 (en) Fusion protein and use thereof
DK1940918T3 (da) Dimercaptanterminerede polythioetherpolymerer og fremgangsmåder til at fremstille og anvende samme
MX346001B (es) Polipeptidos de eritropoyetina animal modificados y sus usos.
EP2808393A3 (en) Fucosylation-deficient cells
TR201900213T4 (tr) Bir sürekli hücre kültüründe bir polipeptit veya ilişkin virüsün üretim metodu.
NZ584893A (en) PORCINE DC-SIGN, ICAM-3 AND LSECtin AND USES THEREOF
WO2008122027A3 (en) Novel electrode
IL196893A0 (en) Site specific incorporation of non-natural amino acids by vertebrate cells
MY181513A (en) Cell culture compositions and methods for polypeptide production
MX2021015070A (es) Inmunomodulacion usando celulas madre de la placenta.
BRPI1008634A2 (pt) "um meio de conexão, um método de fabricação do mesmo e uma conexão de material".
MX2009000520A (es) Metodos para producir combustibles y solventes.
BRPI0819649A2 (pt) método, organismo geneticamente modificado, e, célula de levedura recinbinante
MX2010007716A (es) Combinacion de una proteina de fusion del anticuerpo-il-2 de anti-edb fibronectina y una molecula que se une a celulas b, progenitores de la celula b y/o sus contrapartes cancerigenas.
BR112015021993A2 (pt) composições de cultura celular com antioxidantes e métodos para produção de polipeptídeo
EA201300455A1 (ru) Полипептиды с пермеазной активностью
DK1511761T3 (da) Fremgangsmåde til fremstilling af cykliske peptider
DK1851815T3 (da) Fremgangsmåde til fremstilling af en brændselscellekatode
WO2012145759A3 (en) Methods of protein production and compositions thereof
UA99700C2 (ru) Способ приготовления иммортализированной человеческой клеточной линии
IL292004B2 (en) Composition for reprogramming cells into plasmacytoid dendritic cells or interferon type i-producing cells, methods and uses thereof